A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

NCT06222697

Status	RECRUITING
Sponsor	Bayer
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (4)

- e12 years of age with hemophilia A
- Previously treated with FVIII concentrate(s) (plasma derived or recombinant)
- Patients who have been treated with Jivi (damoctocog alfa pegol) and those for whom the decision to initiate treatment with Jivi was made as per physician's routine treatment practice with any kind of treatment modality (on-demand, prophylaxis, etc.)
- Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion (4)

- Contraindication according to the local authorized indication (including known hypersensitivity to the drug substance or any of its components (e.g., mouse or hamster protein))
- Patients participating in an investigational program with interventions outside of routine clinical practice
- Patients with any other diagnosis of bleeding/coagulation disorder other than hemophilia A
- Patients on immune tolerance induction treatment at the time of enrollment

Locations (1 total)

Many Locations, Multiple Locations, South Korea